GSK656 clinical trials
Also written GSK3036656.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses GSK656 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GSK3036656
- 4
Studies by the year they started
4 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Bedaquiline (1) · OPC-67683 (1) · Isoniazid (1) · Rifampin (1) · Pyrazinamide (1) · Ethambutol (1)
Studies
Open first, then newest update. How each study uses GSK656 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary TuberculosisCompletedPhase 2GlaxoSmithKlineNCT05382312Written as GSK3036656
- A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of AgeCompletedPhase 1GlaxoSmithKlineNCT06354257Written as GSK3036656
- An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary TuberculosisCompletedPhase 2GlaxoSmithKlineNCT03557281Written as GSK3036656
- First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT03075410Written as GSK3036656
Codes
What other systems call GSK656 · ClinicalTrials.gg INT000815
- MeSH (NLM) C000624292GSK656One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000624292 | GSK656 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.